(Stroke. 1999;30:2326-2330.)
© 1999 American Heart Association, Inc.
Original Contributions |
Correspondence to Dr Ka Sing Wong, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. E-mail ks-wong{at}cuhk.edu.hk
| Abstract |
|---|
|
|
|---|
MethodsWe conducted a prospective study of consecutive patients with acute stroke who were admitted to 36 participating hospitals in China, India, Indonesia, Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. With the use of a simple identical data sheet, we recorded the demographics and cardiovascular risk factors of each patient. Early death was defined as death on discharge from the acute hospital.
ResultsWe enrolled 2403 patients with ischemic stroke and 783 patients with intracerebral hemorrhage. Among patients with ischemic stroke, previous use of antiplatelet drugs (adjusted odds ratio [OR] 0.53; 95% confidence interval [CI] 0.30 to 0.95) and relatively young age group 56 to 75 years (OR 0.65; 95% CI 0.42 to 1.00) were protective factors; atrial fibrillation (OR 2.23; 95% CI 1.40 to 3.57), ischemic heart disease (OR 2.03; 95% CI 1.37 to 3.05), diabetes (OR 1.52; 95% CI 1.04 to 2.22), and ex-smoker status (OR 2.18; 95% CI 1.18 to 4.05) were risk factors for early death. Among patients with intracerebral hemorrhage, hypertension (OR 0.56; 95% CI 0.38 to 0.82) and young age group 56 to 75 years old (OR 0.55; 95% CI 0.34 to 0.87) were associated with lower death rate, whereas diabetes (OR 1.74; 95% CI 1.01 to 2.98) was a risk factor for early death.
ConclusionsIn Asian patients with stroke, previous use of antiplatelet drugs nearly halved the risk of early death in patients with ischemic stroke, whereas atrial fibrillation, ischemic heart disease, diabetes, and ex-smoker status were risk factors for early death. Among patients with intracerebral hemorrhage, diabetes was associated with early death, whereas young age group and hypertension were associated with lower death rates, though no clear explanation for the hypertension association could be discerned from the data available.
Key Words: antiplatelet agents hypertension intracerebral hemorrhage mortality risk factors stroke, ischemic
| Introduction |
|---|
|
|
|---|
Despite the importance of stroke in Asia, there have been very few prospective international studies of stroke within this region. Stroke is a heterogeneous disease. Ischemic and hemorrhagic strokes are the 2 main types of stroke, with very different pathogenesis and outcome. Ideally, the risk factors for death in each type of stroke should be studied separately, but limited data are available. We sought to investigate the risk factors for early death in patients with ischemic stroke or intracerebral hemorrhage (ICH) by performing a prospective international hospital-based study of consecutive patients with acute stroke in Asia.
| Subjects and Methods |
|---|
|
|
|---|
|
Stroke types were classified into ischemic stroke, ICH, subarachnoid hemorrhage (SAH), and uncertain stroke type. Either computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain was required for the diagnosis of ischemic stroke and intracerebral and SAH. Patients without neuroimaging investigations were classified as having uncertain stroke type. Statistical analyses included only patients with neuroimaging that did not show SAH.
Statistical Analyses
Separated statistical analyses were performed for
ischemic stroke and ICH. Univariate
analysis was first performed with demographic characteristics
and the risk factors of stroke by cross-tabulations with
2 or Fisher's exact tests for the unadjusted
odds ratios (ORs). Then, a logistic multiple regression model was
used4 because its ß-coefficient might be transformed as
adjusted ORs for each independent factor, which indicated the magnitude
of the risk factor effect. A logistic regression model determined the
factors that might significantly influence early death. All probability
values shown were based on the Wald test. In both
univariate and multivariate
analyses, ORs with 95% confidence intervals (CIs) were used to
estimate the effects of each factor on the discharge status after
stroke admission. The independent variables included demographic
variables: age (classified into 3 groups as
55 years old, 56 to
75 years old, and
76 years old) and sex. Other risk factors were
entered as categorical data. All statistical analyses were
performed with the SPSS 8.0 package, with statistical significance at
0.05 (2-sided).
| Results |
|---|
|
|
|---|
|
According to our classification, 2403 patients had ischemic
stroke, 783 had ICH, 114 patients had SAH, and 370 had uncertain stroke
type. Patients with SAH or uncertain stroke type were excluded from
further analysis. Case fatality for ischemic stroke was
8.8% and for ICH, 29.8%. Death occurred after a mean of 12.9 days
(median 6 days) after admission for ischemic stroke and 7.3
days (median 3 days) for ICH. The estimated ORs for early death
obtained among patients with ICH and patients with ischemic
stroke, together with the 95% CIs and probability values, are shown in
Table 2
. In summary, among patients with
ischemic stroke, prior use of antiplatelet drugs before
stroke (OR 0.53; 95% CI 0.30 to 0.95) and relatively younger age group
56 to 75 years (OR 0.65; 95% CI 0.42 to 1.00) were protective factors,
whereas atrial fibrillation (OR 2.23; 95% CI 1.40 to 3.57),
ischemic heart disease (OR 2.03; 95% CI 1.37 to 3.05),
diabetes (OR 1.52; 95% CI 1.04 to 2.22), and ex-smoker status (OR
2.18; 95% CI 1.18 to 4.05) were independent risk factors for early
death. Among patients with ICH, hypertension (OR 0.56; 95% CI 0.38 to
0.82) and younger age group of 56 to 75 years (OR 0.55; 95% CI 0.34 to
0.87) were significant protective factors, whereas diabetes (OR 1.74;
95% CI 1.01 to 2.98) was a risk factor for early death.
|
A post hoc subgroup analysis was performed to investigate whether there were regional differences in death rates. Because China provided the largest number of patients in the data set, China was used as the reference group in the multivariate analysis including demographics and risk factors. Among patients with ischemic stroke, Korea (OR 0.23; 95% CI 0.11 to 0.46) and India (OR 0.19; 95% CI 0.07 to 0.49) had significantly lower death rates, whereas Thailand (OR 5.30; 95% CI 2.86 to 9.84) had significantly higher death rates. Among patients with ICH, Korea (OR 0.03; 95% CI 0.00 to 0.23) and India (OR 0.42; 95% CI 0.19 to 0.92) had significantly lower death rates, whereas Thailand (OR 2.27; 95% CI 1.11 to 4.63) had significantly higher death rates.
| Discussion |
|---|
|
|
|---|
In patients with ischemic stroke, our data show that atrial fibrillation and ischemic heart disease are independent risk factors for early death. Among different types of ischemic stroke, cardioembolic stroke tends to be more severe.8 In 2 population-based studies in Rochester and in Framingham, the ORs for stroke death were 1.7 and 2.0 for patients with atrial fibrillation.9 10 The magnitude of the hazard associated with atrial fibrillation is similar to our data, which show an OR of 2.23. The concurrence of our results with results from studies in other populations further strengthens the external validity of our study.
Our data also suggest that ex-smokers have a higher mortality rate compared with that of current smokers. We suspect that there are confounding variables such as malignancy and chronic lung diseases that might prompt patients to stop smoking. The presence of comorbidity may be the cause of the increased mortality rates. When we reclassify patients as "never-smoker" or "ever-smoker," there is no difference in mortality rates between these 2 groups (OR 0.97; 95% CI 0.64 to 1.48).
One important finding of this study was the observation that prior use of antiplatelet drugs, mainly aspirin, nearly halved the risk of early death among patients with ischemic stroke. The benefit of antiplatelet drugs in the secondary prevention of stroke and cardiovascular diseases is now firmly established.11 However, ischemic stroke may still occur in patients taking regular antiplatelet drugs. In this group of patients, it remains uncertain whether prophylactic use of aspirin reduces the severity of subsequent stroke. In other clinical situations in which acute arterial occlusion occurs, aspirin has been shown to abate the clinical manifestation.12 In cerebrovascular disease, Grotta and colleagues13 showed that patients who had a stroke while taking aspirin tended to have a less severe stroke. Recently, Karepov and colleagues14 observed a 34% reduction in risk of early death among 2113 patients with ischemic stroke. Although the risk reduction of early death was not statistically significant in this study, only 125 (6%) patients were taking aspirin and thus the interpretation might be subject to a type 2 error. In our AASAP Stroke Registry, 347 (14%) patients were taking aspirin. With improved statistical power, our data confirmed the protective effect of aspirin in reducing the risk of early death. Another important difference was that in Karepov and colleagues' study, only 78% of patients had CT scans done. Patients with ICH could have been included in the analysis, probably diluting the benefit of aspirin. In contrast, our analysis only included those patients with neuroimaging examinations. The mechanism of the protective effects of aspirin is presumably related to its antiplatelet effect. Inhibited platelet aggregation may reduce thrombus formation and propagation, resulting in a smaller brain infarct. Moreover, there has been recent interest in the neuroprotective effects of aspirin on ischemic brain.15 16
Although ischemic stroke outnumbered ICH by 3 to 1, there were more deaths in the patients with ICH (233 vs 211 deaths) because of the high death rate of ICH. Our data suggest that hypertension is associated with significantly lower mortality rates in patients with ICH. This finding is intriguing and has not been well documented in the literature. It is likely that nonhypertensive patients had other underlying causes such as amyloid angiopathy or occult angioma,17 which might be more severe and cause worse outcomes. This observation needs to be replicated in future studies, which should include more detailed information regarding the blood pressure levels, types of antihypertensive drugs taken, whether blood pressures were acutely lowered, and evidence of end-organ damage from long-standing hypertension. Because this study was the first of its kind in this region and with limited resources, we did not record these variables in our data sheet.
A post hoc subgroup analysis showed that patients in Thailand had significantly higher death rates, whereas patients in Korea and India had significantly lower death rates irrespective of the stroke type. These findings should be viewed with caution because the criteria for hospital admission were different in different countries. For example, the Siriraj Hospital in Thailand is a center of excellence for stroke and therefore might attract patients with more severe stroke from other parts of Bangkok. These differences, however, should not overshadow the similarity of death rates among China, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, and Vietnam.
There are several limitations of this study. Because this was a hospital-based study, patients with mild stroke who did not report to a hospital may have been excluded. However, our findings of some of the well-known prognostic factors such as atrial fibrillation are similar to other population-based studies. There also may be differences in the admitting policies among different participating hospitals. In some hospitals, patients with ICH were admitted to the surgical wards. We tried to overcome this problem by attempting to include all patients with stroke in different departments that we were able to trace. Stroke registries, nevertheless, have contributed substantially toward our understanding of stroke. Other limitations included lack of detailed clinical information of individual patients. For the individual patient, the best predictors for early death relate to the size and location of cerebral hematoma or infarct. Depressed level of consciousness and severe neurological deficits are well-documented poor prognostic factors.18 19 These variables, however, merely reflect the effect of stroke and provide limited information on the stroke mechanism. Risk factors such as diabetes and atrial fibrillation may provide better insight into the underlying cause of stroke in individual patients.
The strength of this study is the prospective design, uniform data acquisition form, and the ability to collect a large number of patients within a short time. More importantly, >93% of patients with stroke had confirmatory CT or MRI scans. Thus we were able to limit the analysis to those patients with neuroimaging while retaining statistical power to identify important risk factors for early death among patients with hemorrhagic and ischemic strokes separately. Subsequently, the observed statistical associations are robust.
In summary, our data suggest that prophylactic use of antiplatelet drugs before stroke reduce the risk of early death in patients with ischemic stroke. This benefit complements the mounting evidence in support of the use of antiplatelet drugs for patients at high risk of ischemic stroke. Advancing age, diabetes, and atrial fibrillation are not only risk factors for stroke but are risk factors for more severe stroke. Among patients with ICH, young age group and hypertension were associated with lower death rates, though no clear explanation for the hypertension association could be discerned from the data available. More importantly, our study shows that it is feasible to conduct a multicenter study on stroke in Asia with very limited resources. This may lay the foundation for further collaborative study of stroke in this region.
| Acknowledgments |
|---|
| Appendix 1 |
|---|
|
|
|---|
Statisticians
J. Lau, LY Xu, A, Tang (The Chinese University of Hong
Kong).
Participating Hospitals and Collaborators
China (817 Patients)
Prince of Wales Hospital, Hong Kong (K.S. Wong, W.W.M. Lam, A.
Wong, R. Kay); Queen Elizabeth Hospital, Hong Kong (C.K. Wong, B. Yuen,
P. Li); Pamela Youde Nethersole Eastern Hospital, Hong Kong (T.H. Tsoi,
C.M. Cheung); Peking Union Medical College Hospital, Beijing (Y.N.
Huang, S. Gao).
Korea (570 Patients)
Seoul National University Hospital, Seoul (S.B. Lee, J.K. Roh,
B.W. Yoon, Y.S. Lee); Kyung Hee University Hospital, Seoul (K.C. Chung,
D.I. Chang); Inha University Hospital, Incheon City (J.H. Rha); Chonbuk
National University Hospital, Cheongju (Y.H. Kim, M.W. Seo); Seoul
Borame City Hospital, Seoul (S.H. Park); Gyeongsang National University
Hospital, Chinju (B.H. Lim); Dong-A University Hospital, Pusam (J.W.
Kim); Dankook University Hospital, Cheonan (J.I. Kim); Chungbuk
National University Hospital, Cheongju (S.H. Han); Eulji General
Hospital, Seoul (B.A. Wie).
Taiwan (404 Patients)
National Taiwan University Hospital, Taipei (J.S. Jeng, P.K.
Yip, T.K. Lee, Y.C. Chang, Z.S. Huang, S.K. Ng, R.C. Chen); Shin-Kong
WHS Memorial Hospital, Taipei (H.C. Chiu, W.C. Hsu).
India (365 Patients)
Bhavnagar Hospital, Bhavnagar (A. Tipnis); Belle Vue Clinic,
Calcutta (S.S. Nandi); Gauhati Medical College, Gauhati (A.
Mahanta); Vijaya Health Center, Madras (D. Arjundas); Willingdon
Hospital, Madras (G. Arjundas); Bombay Hospital, Mumbai (B.S. Singhal);
Baheti Hospital, Nagpur (M. Baheti); Baroda Hospital, Vadodara (K.R.
Buch); Mayo Hospital/Vadodara Hospital, Vadodara (C. Trivedi).
The Philippines (359 Patients)
Jose R. Reyes Memorial Medical Center, Manila (S. Marasigan, H.
Gan); University of Santo Tomas, Manila (G. Gamez, J. Poblete, J.
Navarro, B. Conde, R. Javier, I. David, R. Luzod, E. Ong); Philippines
General Hospital, Manila (E. Bitanga, F.E. Bacsal, R.M. Canlas, C.
Chua, M. Dantes, M. Gose, P. Ramiro, J. Gutierrez, R. Libarnes, L. Lim,
M. Perez, A. Roxas, M.G. Yusay, D. Lardizabal).
Indonesia (299 Patients)
Dr Ciptomangunkusumo, Jakarta (J. Misbach, W. Ali); RS Islam,
Jakarta (J. Misbach, Syahrul).
Vietnam (242 Patients)
Bach Mai Hospital, Hanoi (L.D. Hinh, L.V. Tinh, P.H. Minh, D.B.
Hoa).
Thailand (237 Patients)
Siriraj Hospital, Bangkok (N. Poungvarin, V. Senanarong, R.
Chaisevikul, N. Prayoonwiwat).
Singapore (190 Patients)
Tan Tock Seng Hospital (N.V. Ramani, S.H. Lee, A. Tan, C.B. Tan,
H. Tjia); Singapore General Hospital (H.M. Chang, M.C. Wong, K.
Puvanendran, S.H. Lim, C.P.L.H. Chen, P. Ratnagopal).
Malaysia (187 Patients)
University Hospital, Kuala Lumpur (W.K. Ng); Pakar Perunding
Perubatan, Hospital, Kelang (S.K. Chua, M.R. Jusoh).
Received May 17, 1999; revision received August 16, 1999; accepted August 16, 1999.
| References |
|---|
|
|
|---|
2. Murray CJL, Lopez AD, eds. The Global Burden of Disease. Vol 1. Boston, Mass: Harvard University Press; 1996.
3. Boysen G, Truelsen T. Looking beyond first-ever stroke. Lancet. 1998;351:10731774.[Medline] [Order article via Infotrieve]
4. Afifi AA, Clark V. Computer-Aided Multivariate Analysis. 2nd ed. Belmont, Calif: Lifetime Learning Publications; 1990.
5. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes: the Copenhagen Stroke Study. Stroke. 1994;25:19771984.[Abstract]
6.
NINDS t-PA Stroke Study Group. Generalized efficacy of
t-PA for acute stroke: subgroup analysis of the NINDS t-PA
Stroke Trial. Stroke. 1997;28:21192125.
7.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M.
Mortality from coronary heart disease in subjects with type 2
diabetes and in nondiabetic subjects with and without prior myocardial
infarction. N Engl J Med. 1998;339:229234.
8.
Broderick JP, Phillips SJ, O'Fallon WM, Frye RL,
Whisnant JP. Relationship of cardiac disease to stroke occurrence,
recurrence, and mortality. Stroke. 1992;23:12501256.
9.
Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS,
Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation:
the Framingham Study. Stroke.. 1996;27:17601764.
10. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation: the Copenhagen Stroke Study. Stroke.. 1996;10:17651769.
11.
Hennekens CH, Dyken ML, Fuster V. Aspirin as a
therapeutic agent in cardiovascular disease: a
statement for Healthcare Professionals from the American Heart
Association. Circulation. 1997;96:27512753.
12.
Garcia-Dorado D, Théroux P, Tornos P, Sambola A,
Oliveras J, Santos M, Soler S. Previous aspirin use may attenuate the
severity of the manifestation of acute ischemic syndromes.
Circulation. 1995;92:17431748.
13.
Grotta JC, Lemak NA, Gary H, Fields WS, Vital D. Does
platelet antiaggregant therapy lessen the severity of stroke?
Neurology. 1985;35:632636.
14.
Karepov V, Bornstein NM, Hass Y, Korczyn AD. Does daily
aspirin diminish severity of first-ever stroke? Arch Neurol. 1997;54:13691371.
15.
Grilli M, Pizzi M, Memo M, Spano PF. Neuroprotection by
aspirin and sodium salicylate through blockade of NF-kB activation.
Science. 1996;274:13831395.
16.
Riepe MW, Kasischke K, Raupach A.
Acetylsalicylic acid increases tolerance against
hypoxic and chemical hypoxia. Stroke. 1997;28:20062011.
17. Caplan LR. Intracerebral haemorrhage. Lancet. 1992;339:656658.[Medline] [Order article via Infotrieve]
18. Sacco RL. Risk factors, outcomes, and stroke subtypes for ischemic stroke. Neurology. 1997;40(suppl 4):S39S44.
19.
Hier DB, Edelstein G. Deriving clinical prediction
rules from stroke outcomes research. Stroke. 1991;22:14311436.
This article has been cited by other articles:
![]() |
L. H. Sansing, S. R. Messe, B. L. Cucchiara, S. N. Cohen, P. D. Lyden, S. E. Kasner, and For the CHANT Investigators Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH Neurology, April 21, 2009; 72(16): 1397 - 1402. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Saposnik, A. Baibergenova, M. O'Donnell, M. D. Hill, M. K. Kapral, V. Hachinski, and On behalf of the Stroke Outcome Research Canada (S Hospital volume and stroke outcome: Does it matter? Neurology, September 11, 2007; 69(11): 1142 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Viswanathan, J.-P. Guichard, A. Gschwendtner, F. Buffon, R. Cumurcuic, C. Boutron, E. Vicaut, M. Holtmannspotter, C. Pachai, M.-G. Bousser, et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study Brain, September 1, 2006; 129(9): 2375 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Wong and K. Toyoda Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage Neurology, May 23, 2006; 66(10): 1610 - 1611. [Full Text] [PDF] |
||||
![]() |
P. Saloheimo, T.-M. Lapp, S. Juvela, and M. Hillbom The Impact of Functional Status at Three Months on Long-Term Survival After Spontaneous Intracerebral Hemorrhage Stroke, February 1, 2006; 37(2): 487 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. N. Thomas, B. Tomlinson, A. S.M. Abdullah, V. T.F. Yeung, J. C.N. Chan, and K. S. Wong Association of Erectile Dysfunction With Cardiovascular Risk Factors and Increasing Existing Vascular Disease in Male Chinese Type 2 Diabetic Patients Diabetes Care, August 1, 2005; 28(8): 2051 - 2053. [Full Text] [PDF] |
||||
![]() |
R Fogelholm, K Murros, A Rissanen, and S Avikainen Admission blood glucose and short term survival in primary intracerebral haemorrhage: a population based study J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 349 - 353. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Flibotte, N. Hagan, J. O'Donnell, S. M. Greenberg, and J. Rosand Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage Neurology, September 28, 2004; 63(6): 1059 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. U. Heuschmann, P. L. Kolominsky-Rabas, B. Misselwitz, P. Hermanek, C. Leffmann, R. W. C. Janzen, J. Rother, H.-J. Buecker-Nott, K. Berger, and for The German Stroke Registers Study Group Predictors of In-Hospital Mortality and Attributable Risks of Death After Ischemic Stroke: The German Stroke Registers Study Group Arch Intern Med, September 13, 2004; 164(16): 1761 - 1768. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rosand, M. H. Eckman, K. A. Knudsen, D. E. Singer, and S. M. Greenberg The Effect of Warfarin and Intensity of Anticoagulation on Outcome of Intracerebral Hemorrhage Arch Intern Med, April 26, 2004; 164(8): 880 - 884. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ma, J. Cutter, C. E. Tan, S. K. Chew, and E. S. Tai Associations of Diabetes Mellitus and Ethnicity with Mortality in a Multiethnic Asian Population: Data from the 1992 Singapore National Health Survey Am. J. Epidemiol., September 15, 2003; 158(6): 543 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Eckman, J. Rosand, K. A. Knudsen, D. E. Singer, and S. M. Greenberg Can Patients Be Anticoagulated After Intracerebral Hemorrhage?: A Decision Analysis Stroke, July 1, 2003; 34(7): 1710 - 1716. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Wilterdink, B. Bendixen, H. P. Adams Jr, R. F. Woolson, W. R. Clarke, and M. D. Hansen Effect of Prior Aspirin Use on Stroke Severity in the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Stroke, December 1, 2001; 32(12): 2836 - 2840. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Wong, H. Li, Y. L. Chan, A. Ahuja, W. W.M. Lam, A. Wong, and R. Kay Use of Transcranial Doppler Ultrasound to Predict Outcome in Patients With Intracranial Large-Artery Occlusive Disease Stroke, November 1, 2000; 31(11): 2641 - 2647. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |